by Raynovich Rod | Aug 4, 2016 | Biopharmaceuticals
8/5 After the Close… NASDAQ Up 1.06% The IBB inched up 0.38% to $297.29 while the more volatile XBI did better up 1.07%. Both are still down YTD and trail the QQQ which is up 4.39% YTD. Investors in biotech were not deterred by bad clinical news from...
by Raynovich Rod | Jun 14, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
BIO International 2016 : “Imagine Who You will Meet” was an Appropriate Theme Healthcare Disruption Is Creating Reform BIO 2016 was an excellent meeting as usual because of the opportunity to hear thought leaders, policy makers, scientists and make...
by Raynovich Rod | Jun 5, 2016 | Biopharmaceuticals
Pre-ASCO rally-Three Weeks of gains= 8-15% Every year the ASCO Meeting excites investors because of clinical data being presented on a huge pipeline of oncology products. High expectations have already delivered an ASCO rally so now can the actual clinical data...
by Raynovich Rod | Jun 3, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
BIO International Conference-Trends in the Biotechnology Industry We will be attending BIO International Convention in San Francisco next week and will provide news updates on relevant topics such as Personalized Medicine, biopharma drug policy and pricing, and next...
by Raynovich Rod | Jun 2, 2016 | Clinical Diagnostics and Tools
Update -1 NH closes at $18.59 up 32.79% on volume of 3.3M shares. High was $21 low was $16.11. Market cap is $2.1B. Focus of the Company is personalized healthcare utilizing a unique software platform (NantOS) applying molecular diagnostics and genomics on patient...
by Raynovich Rod | May 31, 2016 | Biopharmaceuticals
Update June 1… After Close Biotech Holds…Uh oh CNBC is talking about biotech. IBB 281.18, XBI 58.18 This stealth rally has been going steady for two weeks but now CNBC and its “Fast Money” show are talking up biotech so is this a jinx? And...
by Raynovich Rod | Apr 27, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Biotech Bear Market: XLV —A Large Cap Healthcare ETF Outperforms We have compared the performance of top mutual funds in the past and thought it would be interesting to see what happens in a bear market which began in September of 2015. Our last review was in...
by Raynovich Rod | Apr 4, 2016 | Biopharmaceuticals
Update 4/6/16 Biotech Rally Picks Up Momentum Today IBB up 4.5%,XBI up 5% Speculative stocks lead the way: BLUE up 10%, VRX up 16.6% ——–Risk on mode continues——— Healthcare Sector Leads the Market Lagging healthcare and biotech...
by Raynovich Rod | Apr 4, 2016 | Biopharmaceuticals
Roche/Genentech Has a Strong Pipeline in Diagnostics and Therapeutics to Drive Moderate Growth in 2016 New Stock Pick: Roche Holding (OTCQX:RHHBY) $30.36 Over the past 3 months we recommended several new buys for the Rayno Biopharma Portfolio emphasizing moderate...
by Raynovich Rod | Mar 14, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Tuesday 12:45pm EDT Update on a red screen day: Healthcare sector lags down 1.6%, biotechs now being crushed IBB down 3.1%,XBI down 5%! ——– Look for Value +Growth Picks in a Biotech Bear Market Marijuana Strengthens Clinical Status Review our...
